All lobbying filings

MEHLMAN CONSULTING, INC.

MEHLMAN CONSULTING, INC. filed a Q1 report for ULTRAGENYX PHARMACEUTICAL, INC. on April 17, 2026, reporting $60,000 in lobbying income.

Lobbying for ULTRAGENYX PHARMACEUTICAL, INC. · Biopharmaceutical Company

All filings by MEHLMAN CONSULTING, INC. · Everything ULTRAGENYX PHARMACEUTICAL, INC. has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 17, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Issues relating to rare disease and patient access. H.R.1262/S. 932 - Give Kids a Chance Act of 2025.

Budget/Appropriations

FY 2027 Appropriations.

Bills named in this filing 2

H.R. 1262
Mikaela Naylon Give Kids a Chance Act
S. 932
Give Kids a Chance Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.